Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note published on Sunday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of BTX stock opened at $0.33 on Friday. Brooklyn ImmunoTherapeutics has a 52-week low of $0.17 and a 52-week high of $10.10. The company has a market capitalization of $19.41 million, a PE ratio of -0.15 and a beta of 4.61. The business’s fifty day moving average is $0.85 and its 200 day moving average is $1.43.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.